Altium Capital Management LP Aeglea Bio Therapeutics, Inc. Transaction History

Altium Capital Management LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$1.87 - $4.77 $549,338 - $1.4 Million	-293,764 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$3.5 - $8.42 $1.11 Million - $2.66 Million	-315,925 Reduced 51.82%	293,764 $1.4 Million
Q2 2021 Aug 13, 2021	BUY	$6.32 - $8.38 $2.16 Million - $2.87 Million	341,936 Added 127.71%	609,689 $4.24 Million
Q4 2020 Feb 16, 2021	BUY	$7.02 - $9.83 $1.88 Million - $2.63 Million	267,753 New	267,753 $2.11 Million

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Altium Capital Management LP with notifications on news.